Pasteur Merieux MSD has launched Avaxim, a new inactivated hepatitis A vaccine, in the UK for the immunization of adults and adolescents over the age of 16. This is the first introduction of the product worldwide. The UK acted as rapporteur for Avaxim in Europe.
The firm notes that a single dose of Avaxim gives patients rapid protection, with 94.3% seroconversion just two weeks after injection. This rate rises to 100% after four weeks, and a booster at six months provides cover for up to 10 years. Avaxim comes in a 0.5ml dose, which Merieux is citing as a competitive advantage over SmithKline Beecham's Havrix, the only other UK-approved hep A vaccine. Avaxim costs L21.60 per dose, the same as Havrix.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze